Slide from Katherine Tuttles presentation, during FLOW session, 61st European Renal Association Congress Conclusion The FLOW trial showed that semaglutide significantly decreased the risk of progression of kidney disease in T2DM, without significant increases in serious adverse events
(PubMed) Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT
The arginine substitution dramatically reduces IGFBP binding affinity by approximately 1,000-fold relative to native IGF-1 while the N-terminal extension contributes to extended circulating stability
Glutathione IV shots deliver a potent, tailored dose of this magical antioxidant directly into your bloodstream, ensuring that nothing is wasted
Consistent Delivery: Patches provide a steady release of GLP-1, which may enhance effectiveness compared to other delivery methods